ADT combined withabiraterone and prednisone in the treatment of a patient with metastatic hormone-sensitive prostate cancer

VernacularTitle:ADT联合阿比特龙及泼尼松治疗转移性激素敏感性前列腺癌一例报告
Author: Chuanbo LI ¹ ; Rui LIN ; Tong REN ; Huaiyuan GUO
Author Information

1. 临沂市肿瘤医院泌尿外科，山东临沂　276000
Keywords: Prostatic neoplasms; Metastatic; Sensitive; Androgen deprivation therapy; Abiriron
From: Chinese Journal of Urology 2021;42(Z1):51-53
CountryChina
Language:Chinese
Abstract: Androgen deprivation therapy (ADT) combined with abiraterone and prednisone.for metastatic hormone sensitive prostate cancer (mHSPC) is proved effective in many researches, but it is not verified in china. We present the case of a 62-year-old man who was referred to our hospital for high-risk mHSPC with the main symptoms of dysuria and weak stream. the level of prostate-specific antigen (PSA) was elevated, and the results of biopsy, magnetic resonance and PET-CT showed prostate cancer with multiple lymph node metastases to the right scapula and right pubic bone (T 3bN 1M 1b). The patients were treated with the combination of ADT plus abiraterone and prednisone. After treatment, the level of PSA and testosterone returned to normal and were well-controlled.